NASDAQ:SIBN

SI-BONE Stock Forecast, Price & News

$29.78
+0.74 (+2.55 %)
(As of 07/28/2021 12:00 AM ET)
Add
Compare
Today's Range
$28.83
$29.90
50-Day Range
$27.97
$33.84
52-Week Range
$16.25
$37.21
Volume255,629 shs
Average Volume271,588 shs
Market Capitalization$977.14 million
P/E RatioN/A
Dividend YieldN/A
Beta1.44
30 days | 90 days | 365 days | Advanced Chart
Receive SIBN News and Ratings via Email

Sign-up to receive the latest news and ratings for SI-BONE and its competitors with MarketBeat's FREE daily newsletter.


SI-BONE logo

About SI-BONE

SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.99 out of 5 stars

Medical Sector

293rd out of 2,210 stocks

Surgical & Medical Instruments Industry

32nd out of 185 stocks

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











SI-BONE (NASDAQ:SIBN) Frequently Asked Questions

Is SI-BONE a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SI-BONE in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SI-BONE stock.
View analyst ratings for SI-BONE
or view top-rated stocks.

What stocks does MarketBeat like better than SI-BONE?

Wall Street analysts have given SI-BONE a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but SI-BONE wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is SI-BONE's next earnings date?

SI-BONE is scheduled to release its next quarterly earnings announcement on Monday, August 2nd 2021.
View our earnings forecast for SI-BONE
.

How can I listen to SI-BONE's earnings call?

SI-BONE will be holding an earnings conference call on Monday, August 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were SI-BONE's earnings last quarter?

SI-BONE, Inc. (NASDAQ:SIBN) released its earnings results on Sunday, May, 2nd. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.40) by $0.03. The firm had revenue of $20.44 million for the quarter, compared to analyst estimates of $19.08 million. SI-BONE had a negative net margin of 56.06% and a negative trailing twelve-month return on equity of 31.92%.
View SI-BONE's earnings history
.

How has SI-BONE's stock price been impacted by COVID-19 (Coronavirus)?

SI-BONE's stock was trading at $15.32 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SIBN shares have increased by 94.4% and is now trading at $29.78.
View which stocks have been most impacted by COVID-19
.

What guidance has SI-BONE issued on next quarter's earnings?

SI-BONE updated its FY 2021 earnings guidance on Monday, May, 17th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $92 million-$94 million, compared to the consensus revenue estimate of $93.17 million.

What price target have analysts set for SIBN?

5 brokerages have issued 12-month price targets for SI-BONE's shares. Their forecasts range from $35.00 to $43.00. On average, they anticipate SI-BONE's share price to reach $40.67 in the next year. This suggests a possible upside of 36.6% from the stock's current price.
View analysts' price targets for SI-BONE
or view top-rated stocks among Wall Street analysts.

Who are SI-BONE's key executives?

SI-BONE's management team includes the following people:
  • Ms. Laura A. Francis, CEO & Director (Age 54, Pay $617.85k)
  • Mr. Anthony J. Recupero, Pres of Commercial Operations (Age 62, Pay $588.58k)
  • Mr. Anshul Maheshwari, Chief Financial Officer
  • Mr. Michael A. Pisetsky, Sr. VP of Operations & Admin., Sec. and Chief Legal Officer (Age 43)
  • Dr. Scott A. Yerby, Sr. VP of Engineering & CTO (Age 53)
  • Mr. Joseph W. Powers, VP of Corp. Marketing (Age 61)
  • Dr. W. Carlton Reckling, Chief Medical Officer & VP of Medical Affairs (Age 59)
  • Mr. Nikolas F. Kerr, Sr. VP of Product, Strategy & Bus. Devel. (Age 49)
  • Ms. Joyce Goto, VP & Corp. Controller (Age 47)

What is Jeffrey Dunn's approval rating as SI-BONE's CEO?

10 employees have rated SI-BONE CEO Jeffrey Dunn on Glassdoor.com. Jeffrey Dunn has an approval rating of 41% among SI-BONE's employees. This puts Jeffrey Dunn in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of SI-BONE's key competitors?

What other stocks do shareholders of SI-BONE own?

When did SI-BONE IPO?

(SIBN) raised $84 million in an IPO on Wednesday, October 17th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is SI-BONE's stock symbol?

SI-BONE trades on the NASDAQ under the ticker symbol "SIBN."

How do I buy shares of SI-BONE?

Shares of SIBN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SI-BONE's stock price today?

One share of SIBN stock can currently be purchased for approximately $29.78.

How much money does SI-BONE make?

SI-BONE has a market capitalization of $977.14 million and generates $73.39 million in revenue each year. The company earns $-43,700,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis.

How many employees does SI-BONE have?

SI-BONE employs 295 workers across the globe.

What is SI-BONE's official website?

The official website for SI-BONE is www.si-bone.com.

Where are SI-BONE's headquarters?

SI-BONE is headquartered at 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050.

How can I contact SI-BONE?

SI-BONE's mailing address is 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050. The company can be reached via phone at 408-207-0700 or via email at [email protected]


This page was last updated on 7/28/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.